Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

thehindu.com -  The Hindu Bureau - VSU signs MoU with Malladi Drugs to make pharma students industry-ready
VSU signs MoU with Malladi Drugs to make pharma students industry-ready
The Hindu –

With the aim of providing students with quality education, technical knowledge and practical skills required in the pharmaceutical industry, Vikrama Simhapuri University (VSU), through its College of Pharmaceutical Sciences, Kavali, has entered…

seekingalpha.com - Edmund Ingham - Rhythm Pharma: Is AstraZeneca/Eli Lilly's Bidding War For Real? Don't Rule It Out
Rhythm Pharma: Is AstraZeneca/Eli Lilly's Bidding War For Real? Don't Rule It Out
Seeking Alpha –

I maintain a 'Hold' on Rhythm Pharmaceuticals, Inc.: takeover upside is credible, but standalone valuation and an uncertain deal make risk/reward unpersuasive. Reported bids include AstraZeneca's $124 per share and a rumored Lilly proposal around…

news-medical.net - Pharma leaders rate ability to act on diagnostic insights just 5.2/10, Diaceutics survey finds
Pharma leaders rate ability to act on diagnostic insights just 5.2/10, Diaceutics survey finds
News-Medical –

Pharmaceutical companies are struggling to translate diagnostic intelligence into coordinated action that helps eligible patients reach appropriate treatment, according to new research from intelligence and engagement company, Diaceutics. The…

thehindubusinessline.com - BL Mumbai Bureau - Piramal Pharma acquisition: Company to buy remaining 26% stake in Yapan Bio
Piramal Pharma acquisition: Company to buy remaining 26% stake in Yapan Bio
The HinduBusinessLine –

Updated - November 19, 2026 at 09:36 AM. Piramal Pharma Limited said it would acquire the remaining 26 per cent equity stake in Yapan Bio Private Limited, a subsidiary of the company, from its existing shareholders. The administrative committee…

marketbeat.com - 365,074 Royalty Pharma PLC $RPRX Shares Sold by Aberdeen Group plc
365,074 Royalty Pharma PLC $RPRX Shares Sold by Aberdeen Group plc
MarketBeat –

Aberdeen Group plc trimmed its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 63.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 213,127 shares of the…

marketbeat.com - Ascendis Pharma A/S (NASDAQ:ASND) EVP Sells 20,000 Shares of Stock
Ascendis Pharma A/S (NASDAQ:ASND) EVP Sells 20,000 Shares of Stock
MarketBeat –

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) EVP Anni Lotte Kirstine Pedersen sold 20,000 shares of the stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $263.89, for a total value of…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares of Stock
Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares of Stock
MarketBeat –

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $68.15, for a total value of $6,815,000.00.

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 232,536 Shares of Company Stock
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 232,536 Shares of Company Stock
MarketBeat –

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 232,536 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $68.87, for a total value of $16,014,754.32. The transaction…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) Stock Price Target Raised at TD Cowen
Royalty Pharma (NASDAQ:RPRX) Stock Price Target Raised at TD Cowen
MarketBeat –

Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its price target hoisted by stock analysts at TD Cowen from $68.00 to $80.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a 'buy' rating on the…

marketbeat.com - Spyglass Pharma (NASDAQ:SGP) Stock: Insider Ra Capital Management, L.P. Buys 1,000 Shares
Spyglass Pharma (NASDAQ:SGP) Stock: Insider Ra Capital Management, L.P. Buys 1,000 Shares
MarketBeat –

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) Director Ra Capital Management, L.P. bought 1,000 shares of Spyglass Pharma stock in a transaction dated Monday, November 16th. The stock was acquired at an average cost of $32.43 per share, for…

themeasure.net - Eleanor Semeraro - SAGE Says: The Power of Purpose in Pharma Advertising
SAGE Says: The Power of Purpose in Pharma Advertising
The Measure –

The pharmaceutical category is one of the most prolific TV advertisers, spending billions of dollars annually across linear and streaming CTV. We asked iSpot SAGE to dig up some of the most effective non-OTC pharma ads from the second half of this…

seekingalpha.com - Justin Miller - Meta: Buy The AI Payoff Before The Capex Fear Fades
Meta: Buy The AI Payoff Before The Capex Fear Fades
Seeking Alpha –

Meta Platforms is a Buy: AI-driven ad pricing supports a $712–$782 base case, despite spending and funding risks. Q3 revenue grew 26% as ad prices rose 14% and impressions increased 10%, showing advertisers are paying more for performance.

seekingalpha.com - Albert Anthony - Cousins Properties: A Sunbelt Trophy Stock In The Once-Beleaguered Office REIT Niche
Cousins Properties: A Sunbelt Trophy Stock In The Once-Beleaguered Office REIT Niche
Seeking Alpha –

Albert Anthony is the pen name of a business author on Amazon and a contributing analyst to investing platforms like Seeking Alpha since 2023, where he has over + 2,000 followers and has covered hundreds of stocks in multiple sectors including…

marketanalysis.com - Robot Market Fight Heats Up as US Orders Jump 25% and Chinese Humanoid Makers Lose CES Visas
Robot Market Fight Heats Up as US Orders Jump 25% and Chinese Humanoid Makers Lose CES Visas
Market Analysis –

Two pieces of news landed within days of each other, and they point in opposite directions. American factories want more robots. Washington wants fewer of them to come from China. The Association for Advancing Automation (A3) says North American…

seekingalpha.com - ALLKA Research - Pfizer: The Patent Cliff Fears Are Overblown
Pfizer: The Patent Cliff Fears Are Overblown
Seeking Alpha –

Pfizer Inc., a Big Pharma player offering a 5.96% dividend yield, remains a controversial choice among long-term retail investors. Most concerns reflect PFE's upcoming patent expiration cycle, which is expected to last about 3 years. However, I…

Receive a Daily briefing on Pharma Industry News

Get Started